EB Families and Clinicians
Epidermolysis Bullosa (EB) is a rare genetic disease characterized by the presence of extremely fragile skin and recurrent blister formation, resulting from minor mechanical friction or trauma. Keraplast is proud to work closely with the epidermolysis bullosa community in the US and other regions of the world, and with the global organization DEBRA.
Through regular use of our advanced wound healing product Keragel T, many families, their care givers and dermatologists have reported benefits in the management of acute wounds, chronic wounds and uninjured skin for children and adults suffering from a variety of forms of epidermolysis bullosa.
Keragel T
Keragel T is a keratin based gel that can be used in the regular management of injured and uninjured skin of people with the condition epidermolysis bullosa. Keragel T is a low viscosity gel designed to be easy to apply to delicate skin. Some families using Keragel T as part of daily wound management have shared their stories, find out more.
Correct usage of keragel T is important to get maximum benefit and make wound management as easy as possible. This is important when using on sensitive wounds that may be painful, and also in managing the stickyness of the product as it dries. Correct usage is described in these guidelines on Keragel T usage for the management of EB.
View this video to see how to use keragel T and have the product dry rapidly and avoid stickiness.
View this video to see how to use keragel T on sensitive wounds that may be painful.
A summary of keragel T and its performance can be found here.
Results of a range of case studies have been reported at dermatology conferences in the US, New Zealand and Australia, can be found here.
FDA Approved for Wound Care
Keragel T is approved by the FDA for use in wound care.
Keragel T has HCPC code A6248 under the medicare programme.
Purchasing Keraplast Wound Care Products
For information on purchasing keraplast wound care products including Keragel T please click here.
